Lantern Pharma Schedules FDA Meeting for HARMONIC Trial Protocol Amendments

Lantern Pharma has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek feedback on proposed protocol amendments to its Phase 2 HARMONIC trial evaluating LP-300 in non-small cell lung cancer. The proposed changes include focusing enrollment on EGFR Exon 21 L858R patients, shifting to a single-arm study design and extending treatment cycles. These amendments are supported by emerging clinical data showing an 8.3-month median progression-free survival and encouraging response rates in this difficult-to-treat population.

The significance of this FDA meeting lies in the potential to refine the trial design to better target a specific genetic subgroup of lung cancer patients who have demonstrated promising responses to LP-300. By concentrating on EGFR Exon 21 L858R mutations, Lantern Pharma aims to optimize the trial for a population with significant unmet medical needs. The shift to a single-arm design could streamline the trial process, while extended treatment cycles may better reflect real-world clinical practice and patient benefit.

This development matters because it represents a strategic pivot in Lantern Pharma's clinical development approach, moving from a broader patient population to a precision oncology focus. The 8.3-month median progression-free survival data in this subgroup suggests potential clinical benefit that warrants further investigation. Successful implementation of these amendments could accelerate the development timeline for LP-300 and provide clearer efficacy signals for this targeted patient population.

The implications extend beyond this specific trial to Lantern Pharma's broader precision oncology strategy. The company leverages artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. This FDA meeting represents a critical step in validating the company's data-driven approach to trial design optimization. The outcome could influence how other companies design precision oncology trials for targeted genetic subgroups.

For investors and the oncology community, this announcement signals progress in Lantern Pharma's clinical pipeline advancement. The company's newsroom at https://ibn.fm/LTRN provides ongoing updates about these developments. The proposed trial amendments, if approved by the FDA, could potentially lead to more efficient clinical development and clearer efficacy data for LP-300 in a defined patient population with limited treatment options.